MRNA
MRNA Blow Off Top ConfirmedMRNA broke out of $100 hitting $178 within 4 days on high volume and multiple gap ups. This is significant evidence of a blow off top. Afterwards, we printed a daily bullish engulfing pattern then corrected upwards for 5 days before printing another daily engulfing pattern. The target is $100, which completes the blow off top move and the 1.618 extension of the Wave A move. Blow off tops have sharp moves and just as sharp reversals. I'd expect to see $100 by next week.
MRNA Moderna vaccine 94.5% effective in Phase 3 trial!This was my previews post about Moderna:
The indicators are still bullish. The price of the stock grew 5X since the beginning of the year.
11/16/2020 Oppenheimer Boost Price Target ➝ $157.00
11/16/2020 Piper Sandler Boost Price Target ➝ $166.00
The traditional method of creating vaccines – introducing a weakened or dead virus, or a piece of one, to stimulate the body's immune system – takes over a decade on average, according to a 2013 study. One pandemic flu vaccine took over eight years while a hepatitis B vaccine was nearly 18 years in the making.
Moderna's vaccine went from gene sequencing to the first human injection in 63 days.
Moderna and BioNTech, for example, are also applying mRNA technology to experimental cancer medicines.
BioNTech's vaccine, for example, must be transported at minus 70 degrees Celsius, though Moderna said on Monday it can ship its candidate in normal refrigerators. (Reuters)
If you are interested to test some amazing BUY and SELL INDICATORS, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
MRNA breaking out on vaccines breakthrough.Moderna says its vaccine is 94.5% effective in preventing COVID-19
Reuters
Moderna says its vaccine is 94.5% effective in preventing COVID-19
Julie Steenhuysen and Michael Erman
Mon, November 16, 2020, 7:58 PM GMT+8
By Julie Steenhuysen and Michael Erman
Nov 16 (Reuters) - Moderna Inc said on Monday its experimental vaccine was 94.5% effective in preventing COVID-19 based on interim data from a late-stage clinical trial, becoming the second U.S. company in a week to report results that far exceed expectations.
Together with Pfizer Inc's vaccine, also shown to be more than 90% effective, and pending more safety data and regulatory review, the United States could have two vaccines authorized for emergency use in December with as many as 60 million doses of vaccine available by the year's end.
Next year, the U.S. government could have access to more than 1 billion doses just from the two vaccine makers, more than needed for the country's 330 million residents.
The vaccines, both built using new technology known as messenger RNA or mRNA, represent powerful new tools to fight a pandemic that has infected 54 million people worldwide and killed 1.3 million. The news also comes at time when COVID-19 cases are soaring, hitting new records in the United States and pushing some European countries back into lockdowns.
"We are going to have a vaccine that can stop COVID-19," Moderna President Stephen Hoge said in a telephone interview.
Moderna's interim analysis was based on 95 infections among trial participants who received either a placebo or the vaccine. Of those, only five infections occurred in those who received the vaccine, which is administered in two shots 28 days apart.
A key advantage of Moderna's vaccine is that it does not need ultra-cold storage like Pfizer's, making it easier to distribute. Moderna expects it to be stable at standard refrigerator temperatures of 2 to 8 degrees Celsius (36 to 48°F) for 30 days and it can be stored for up to 6 months at -20 degrees Celsius.
Stocks To Watch This Week Nov 14I went through and created a watchlist for names that have held up well in this choppy environment. Most of these names are at or near all time highs or multi year highs. There are 40 total stocks on this list. Many of these have IPO'd in the last few years and still have a growth story ahead of them. There are also some financial stocks which may be starting to outperform the broader market. Know your time frame and risk tolerance, grab a pencil and paper and jot down the names that look interesting to you and then make the trade your own. Good Luck!
TT Blackbox $MRNA Bearish Swing TradeGreen Line - Entry Target
Red Line - Exit Target
Pink Line - Stop-Loss
Highly suggest using Google to Search "Transparent Traders" if you're trying to get to the next level.
Transparent Traders exists to solve the critical issues facing our traders, both large and small. Our unique approach is not only what differentiates us, but also what makes us successful.
Our advanced Blackbox uses custom algorithms & predictive A.I. to locate the most accurate day or swing trades for the best chance of success.
MRNA 8H: BEST Level to BUY/HOLD 80% gains(SL/TP)(STOCKS)Why get subbed to me on Tradingview?
-TOP author on TradingView
-15+ years experience in markets
-Professional chart break downs
-Supply/Demand Zones
-TD9 counts / combo review
-Key S/R levels
-No junk on my charts
-Frequent updates
-Covering FX/crypto/US stocks
-24/7 uptime so constant updates
MRNA 8H: BEST Level to BUY/HOLD 80% gains(SL/TP)(STOCKS)
IMPORTANT NOTE: speculative setup. do your own
due dill. use STOP LOSS. don't overleverage.
🔸 Summary and potential trade setup
::: MRNA 8hour chart review and outlook
::: Biotech sector outperforming market
::: Currenly in accumulation stage
::: Buying low near range lows
::: is the best strategy BULLS
::: wait for pullback/dips and BUY IT
::: recommended strategy: BUY LOW 55 USD
::: SL 45 US TP is 95/100 USD +80%/+100% gains
::: BUY/HOLD setup
::: DO NOT expect overnight gains
::: This is stock market
::: Not casino in Macau
🔸 Supply/Demand Zones
. N/A
🔸 Why should I follow your setups?
:::Check track record it's all been posted
::: MRNA 200%+ gains, NVAX 300% gains, REG 60%
::: AMD 40% gains and a lot more in 2020
LONG $DGX ER run up ($MRNA $GILD $INO $SPY)see charts at www.tradingview.com
$DGX Entry 120
Target 1 $125
Target 2 $130
Why DGX?
FDA Authorizes Quest Diagnostics COVID-19 Nasal Specimen Self-Collection Kit for Emergency Use
With Covid wave 2 on the rise, this could be a huge player.
www.prnewswire.com
What is DGX?
Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, United Kingdom, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Long Gild - Covid Drug ($MRNA $GSK $INO $SPY $PFE $JNJ $MRK)see full chart at www.tradingview.com
Gild
Entry $62 area
Target 1 $67
Target 2 $71
stoploss $59
Why this play?
Trump used Gild's drug as part of his treatment, if he pulls thru with a full recovery. they will probably start pumping the news about this company and it'll finally have enough momentum to move back to the upside.
What is Gild?
Gilead Sciences, Inc., is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
Notable price upgrades
Sep-30-20 Resumed Jefferies Buy $78
Sep-15-20 Upgrade Maxim Group Hold → Buy $88
My two cents on my most profitable traded stock this year, MRNAI have traded MRNA more than any other stock. Even if you lack the experience and know-how of trading, following some basics trends will give you a high winning percentage with this stock.
1) Finding the premarket high and shorting the stock close to that gives you about an 85% chance of a 50cent-$1 move before market opens.
2) A lot of the news on this stock is old and reused. Today for example there is news that seniors exhibit very few health issues with the stock. This is old news.
3) With every single run up including the first major one close to $100 a few months back, MRNA has flushed 100% of the time with no ability to maintain the premarket levels.